Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MYND Life Sciences Inc C.MYND

Alternate Symbol(s):  MYNDF

MYND Life Sciences Inc. is a Canada-based life science based, neuro-pharmaceutical drug development company. The Company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials, with an initial focus on major depressive disorder (MDD). Its lead development program, referred to as the human mycogene modulation program (HMM), is... see more

Recent & Breaking News (CSE:MYND)

MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment

Newsfile 4 days ago

MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business

Newsfile November 12, 2024

MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.

Newsfile January 30, 2024

Mynd.ai, Inc. Consummates Merger Transaction

PR Newswire December 13, 2023

MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer

Newsfile December 5, 2023

Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences

Newsfile December 4, 2023

MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.

Newsfile October 25, 2023

MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures

Newsfile September 11, 2023

MYND Life Sciences Inc. Has Management CTO Revoked

Newsfile May 9, 2023

MYND Life Sciences Inc. Provides Default Status Report

Newsfile April 25, 2023

MYND Life Sciences Inc. Provides Default Status Report

Newsfile April 12, 2023

MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report

Newsfile March 28, 2023

MYND Life Sciences Inc. Achieves a Major Milestone and Provides Default Status Report

Newsfile March 14, 2023

MYND Life Sciences Inc. Granted Management Cease Trade Order

Newsfile March 1, 2023

MYND Life Sciences Announces the Sale of Leasehold Tenant Improvements and Health Canada Cannabis License

Newsfile February 9, 2023

MYND Life Sciences Announces Stock Option Grant

Newsfile August 10, 2022

Mynd Life Sciences Terminates Proposed Transaction with Tidal Psychedelics

Newsfile June 29, 2022

MYND Life Sciences (CSE:MYND) celebrates Dr. Wilf Jefferies induction as a National Academy of Inventors Fellow

Brieanna McCutcheon  June 17, 2022

MYND Life Sciences Announces Chief Scientific Officer, Dr. Wilf Jefferies, Induction as a National Academy of Inventors Fellow

Newsfile June 17, 2022

MYND Life Sciences (CSE:MYND) announces innovation in psilocybin dosing

Trevor Abes  June 1, 2022